Clinical trials: sponsored by Jonsson Comprehensive Cancer Center
Locally Advanced Head and Neck Carcinoma
Soylent in Reducing Gastrostomy Tube Rates in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemoradiotherapy
This phase II trial studies Soylent in reducing gastrostomy tube rates in patients with head and neck cancer that has spread to nearby tissues or lymph nodes (locally advanced) who are undergoing chemoradiotherapy.
- Trial name
- NCT07242365
- Testing
- Soylent Graham Dietary Supplement, Laboratory Biomarker Analysis, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Bladder Carcinoma, Cervical Carcinoma
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
This exploratory study investigates how an imaging technique called 68Ga-FAPi-46 PET/CT can determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues in patients with cancer.
- Conditions
- Bladder Carcinoma, Cervical Carcinoma, Cholangiocarcinoma, Hematopoietic and Lymphoid Cell Neoplasm
- Trial name
- FAPI PET RDRC (NCT04459273)
- Testing
- Computed Tomography, Gallium Ga 68 FAPi-46, Positron Emission Tomography
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8
Image-Guidance and Online Adaptation With Stereotactic Body Radiation Therapy for the Treatment of Localized Prostate Cancer, MANTICORE Trial
This clinical trial studies the side effects of image-guidance and online adaptation with stereotactic body radiation therapy (SBRT) for the treatment of patients with prostate adenocarcinoma that has not spread to other parts of…
- Conditions
- Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
- Trial name
- NCT07276438
- Testing
- Biospecimen Collection, Computed Tomography, CT-guided Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 186 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Glioma, Malignant Brain Neoplasm
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
This phase I trial studies how well zirconium (Zr)-89 crefmirlimab berdoxam and immuno-positron emission tomography (PET) identifies areas of immune cell activity in patients with brain tumors that can be removed by surgery…
- Conditions
- Glioma, Malignant Brain Neoplasm, Meningioma, Metastatic Malignant Neoplasm in the Brain
- Trial name
- NCT06650163
- Testing
- Advanced Magnetic Resonance Imaging, Brain Surgery, Electronic Health Record Review
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Head and Neck Carcinoma, Localized Head and Neck Carcinoma
Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy for Palliative Head and Neck Cancer Treatment (PULS-Pal)
This trial tests how well personalized ultra fractionated stereotactic adaptive radiotherapy (PULSAR) works together with HyperArc© radiation treatment planning technology for palliative (holistic pain and symptom control) tumor…
- Conditions
- Head and Neck Carcinoma, Localized Head and Neck Carcinoma, Metastatic Head and Neck Carcinoma, Recurrent Head and Neck Carcinoma
- Trial name
- PULS-Pal (NCT06572423)
- Testing
- Personalized ultrafractionated stereotactic adaptive radiotherapy, Volume Modulated Arc Therapy, Computed Tomography
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Malignant Brain Neoplasm, Metastatic Malignant Neoplasm in the Brain
Advanced Magnetic Resonance Imaging for the Identification of Recurrent Brain Tumors and Radiation Necrosis
This clinical trial studies whether advanced magnetic resonance imaging (MRI) techniques, including diffusion-relaxation correlation spectrum imaging (DR-CSI) and sodium imaging, can be used to identify the difference between…
- Trial name
- NCT07339085
- Testing
- Advanced Magnetic Resonance Imaging, Biospecimen Collection, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Thyroid
Randomized Trial Comparing Performance of Molecular Markers for Indeterminate Thyroid Nodules
The purpose of this study is to compare the performance of Afirma GSC and ThyroSeq v.3 in indeterminate thyroid nodules to determine which test can allow more patients to avoid unnecessary surgery and preserve quality of life.
- Trial name
- NCT02681328
- Testing
- Afirma GEC, ThyroSeq v.2, Afirma GSC
- Where
- United States
- Volunteers
- 328 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
Vascular Optimized Radiotherapy Tuned to Critical Structures for Erectile Function Using High-Precision X-Ray Treatment
With people living longer after being treated for prostate cancer, quality of life has become a concern when considering the treatment plan.
- Trial name
- VORTEX (NCT07293585)
- Testing
- Neurovascular sparing stereotactic body radiation therapy
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Breast Cancer Screening, Artificial Intelligence (AI)
A Trial Comparing Screening Mammography With and Without Assistance From Artificial Intelligence for Breast Cancer Detection and Recall Rates in Adult Patients
The goal of this clinical trial is to compare patient-centered outcomes when screening digital breast tomosynthesis (DBT) exams are interpreted with versus without a leading FDA-cleared artificial intelligence (AI)…
- Trial name
- NCT06934239
- Testing
- Artificial intelligence (AI) decision-support tool
- Where
- 6 sites in United States
- Volunteers
- 400,000 people, healthy volunteers welcome
- Sponsor
- Jonsson Comprehensive Cancer Center
Malignant Neoplasm
Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies
This phase II trial will examine whether genetically reprogramming a patient's disease fighting white blood cells may build an immune response to kill cancer cells that express the NY-ESO-1 protein.
- Trial name
- NCT01697527
- Testing
- aldesleukin, fludarabine phosphate, cyclophosphamide
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Colorectal Carcinoma
Implementation Research to Increase Colorectal Cancer Screening Rates Among Low Income and Ethnic Minority Groups
This clinical trial implements research strategies to increase colorectal cancer (CRC) screening rates among low income and ethnic minority groups.
- Trial name
- NCT06090643
- Testing
- Best Practice, Consultation, Educational Intervention
- Where
- United States
- Volunteers
- 9,745 people, healthy volunteers welcome
- Sponsor
- Jonsson Comprehensive Cancer Center
Colorectal Carcinoma
Improving Colonoscopy Surveillance for Patients With High Risk Colon Polyps
This clinical trial tests a multilevel intervention at the clinic, provider and patient levels, to improve colonoscopy surveillance in patients with high risk colon polyps.
- Trial name
- NCT06376565
- Testing
- Best Practice, Communication Intervention, Interview
- Where
- United States
- Volunteers
- 1,680 people, healthy volunteers welcome
- Sponsor
- Jonsson Comprehensive Cancer Center
Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
This phase Ib trial studies how well pembrolizumab works with combination chemotherapy in treating participants with small cell/neuroendocrine cancers of the urothelium or prostate that has spread to nearby tissue or lymph nodes…
- Conditions
- Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma
- Trial name
- NCT03582475
- Testing
- Carboplatin, Cisplatin, Docetaxel
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Lung Adenocarcinoma
An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer
The phase I/II trial assess the safety and efficacy of a new positron emission tomography (PET) test for early diagnosis of lung cancer.
- Trial name
- NCT05558904
- Testing
- Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside, Computed Tomography, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Glioblastoma, Recurrent Glioblastoma
Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma
This clinical trial uses a type of imaging scan called magnetic resonance imaging (MRI) to study brain tumor biology in patients with glioblastoma that can be removed by surgery (resectable).
- Conditions
- Glioblastoma, Recurrent Glioblastoma, Resectable Glioblastoma
- Trial name
- NCT06090903
- Testing
- Biospecimen Collection, Magnetic Resonance Imaging, Medical Chart Review
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Breast Carcinoma, Lung Carcinoma
Utilizing Advocates and Supporters to Increase Lung Cancer Screening Rates in Eligible Participants
This clinical trial assesses the use of advocates and supporters of breast and lung cancer screening to increase lung cancer screening rates amongst eligible participants.
- Trial name
- NCT05978128
- Testing
- Health Education, Health Promotion and Education, Patient Navigation
- Where
- United States
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Jonsson Comprehensive Cancer Center
Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
This phase II trial investigates how well trastuzumab deruxtecan works alone or in combination with anastrozole in treating patients with HER2 low, hormone receptor positive breast cancer.
- Conditions
- Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT04553770
- Testing
- Anastrozole, Therapeutic Conventional Surgery, Trastuzumab Deruxtecan
- Where
- 9 sites in United States
- Volunteers
- 88 people
- Sponsor
- Jonsson Comprehensive Cancer Center
PSA Level Greater Than 0.03, PSA Progression
Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery
This phase II trial studies how well stereotactic body radiation therapy works in treating patients with prostate cancer that has not spread to other parts of the body and have undergone surgery.
- Conditions
- PSA Level Greater Than 0.03, PSA Progression, Stage I Prostate Adenocarcinoma AJCC (American Joint Committee on Cancer ) v7, Stage II Prostate Adenocarcinoma AJCC v7
- Trial name
- NCT03541850
- Testing
- Antiandrogen Therapy, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 92 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Ovarian Cancer
Value-based Integrated Recommendation Software Guiding Ovarian Cancer Treatment (VIRGO2)
This study will evaluate the use of a mobile application in improving the patient-reported health outcome measures (PROMIS) for patients diagnosed with advanced stage ovarian, fallopian tube, and primary peritoneal cancer.
- Trial name
- VIRGO (NCT05523700)
- Testing
- Mobile Application
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer
Prostate cancer is the most common cancer in men and the second leading cause of cancer death in men. The purpose of this research study is to compare prostate cancers treated with hormone therapy versus prostate cancers treated…
- Trial name
- NCT01990196
- Testing
- degarelix, enzalutamide, trametinib
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Jonsson Comprehensive Cancer Center